Method for screening a drug ameliorating insulin resistance
CA 2474353 A1 · Owner: Nakano, Ryosuke · Inventors: Nakano, Ryosuke; Yokota, Hiroyuki; Inabe, Kazunori
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
It is intended to disclose a method of screening a protein which liganddependently interacts with PPAR and is highly useful as a tool for screening a drug improving insulin resistance. Using this method a main effect ligand-, dependent PPAR-binding molecule ECHLP a main effect ligand-selective , PPAR.gamma. acting factor FLJ13111 and a side effect ligand-dependent PPARbinding molecule AOP2 are obtained. It is also intended to disclose a screening system for a drug improving insulin resistance selectively exerting the main effect without causing any side effect which is constructed by using PPAR-interacting ECHLP, PPAR-interacting FLJ13111 and PPAR-interacting AOP2. It is furthermore …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 22, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 22, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 22, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.